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he vertebrate immune system contains sufficient
diversification elements to recognize a vast array of
antigens with high affinity and specificity. As such,
antibodyantigen complexes are valuable model sys-
tems to study molecular recognition.1,2 Conforma-
tional changes upon binding can be intimately linked to
function, and extensive studies have been completed to try to
understand both the structural and dynamic components of
antibodyantigen recognition.3,4 High-resolution structures
of free antibody fragments, free antigens, and their complexes
are known for some interactions, permitting a full characteri-
zation of the contacts and conformational adaptations
involved in complex formation.5–11 Recent studies have uti-
lized techniques such as cryo-electron tomography, atomic
force microscopy, and fluorescence resonance energy transfer
to describe the time course of conformational rearrangement
during binding.12–14
Antibodies that bind DNA (anti-DNA) are a hallmark of
the autoimmune disease systemic lupus erythematosus
(SLE). A subset of anti-DNA form complexes localized to the
glomerular basement membrane of the kidney where thy can
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illicit nephritis, which is responsible for the morbidity and
mortality associated with lupus.15,16 In previous studies, we
generated a panel of anti-ssDNA monoclonal antibodies
(mAbs) from a lupus prone mouse in attempts to differenti-
ate pathogenic and benign anti-DNA.17 Only one mAb in
our panel, 11F8, induces nephritis when administered to
healthy mice.18 Binding site selection experiments for 11F8
reveal preference for a single high affinity consensus ssDNA,
1, whose sequence and secondary structure are related to
DNA antigens eluted from kidney tissue of SLE patients
(Figure 1).19–24 Selection experiments for clonally related
nonpathogenic mAbs 9F11 and 15B10 revealed that these
mAbs are not sequence-specific, and only display a preference
for thymine-rich sequences.25 Interestingly, the primary
sequence of 11F8 differs from 9F11 and 15B10 by less than
five amino acids localized in the variable region of the heavy
chain.28
Somatic mutation from serine to arginine at residue 31 of
the variable heavy chain (31VH) is the primary mediator of
11F8 sequence-specificity.29 Mutagenesis experiments suggest
a salt bridge and hydrogen bond interaction, and our data-
driven model reveals a bidentate hydrogen bond between
R31VH with
C91 that likely contributes to specificity.26,30 Mod-
eling experiments suggested that while the two ligated states
(11F81 and R31S11F81) are related in structure, the 11F8
interface consists of additional residues when arginine is at
31VH as compared to serine.
30 Further, the per residue back-
bone root mean square deviations for the light chain comple-
mentarity determining regions (LCDRs) (1.6 6 0.3 Å), heavy
chain complementrity regions (HCDRs) (1.8 6 0.4 Å), and
ssDNA (5.1 6 2.2 Å) were slightly larger albeit still within
error for the 11F81 complexes with respect to the R31S11F81
complexes (1.5 6 0.3 Å, 1.66 0.5 Å, and 3.6 6 1.2 Å, respec-
tively), suggesting that somatic mutation to arginine may
afford greater binding-site flexibility during recognition.
Here we report a method based on the distance-depend-
ent technique of fluorescence resonance energy transfer
(FRET) in conjunction with stopped-flow measurements, to
directly assess the kinetics and relative amplitudes of binding
site conformational changes during mAbssDNA association.
FRET amplitudes during association for complexes formed
between fluorescein labeled 11F8 and tetramethylrhodamine
labeled 1 are larger with arginine at 31VH with respect to ser-
ine. Thus, our R31S11F81 system likely illustrates how the
conserved ssDNA recognition hot spot (Y32VL, a hydrogen
bonding side chain at 91VL, and an aromatic at the tip of
HCDR3) predisposes mAbs for thymine recognition, afford-
ing thymine intercalation at the binding site with minimal
conformational change.31 We hypothesize that following so-
matic mutation to arginine at 31VH, greater conformational
change during 11F81 association affords additional pro-
teinssDNA contacts that result in sequence-specificity.
MATERIALS AND METHODS
11F8 Cysteine Variant Expression, Purification,
and Labeling
A his-tagged single chain 11F8 construct cloned into pET-28b(+)







and double mutants containing R31SVH and each of the aforemen-
tioned six variants of 11F8 were constructed using site-directed
mutagenesis according to the Quickchange protocol (Stratagene,
La Jolla, CA). Successful incorporation of each mutation was con-
firmed by DNA sequencing. Large-scale expression and purification
were performed as described for the wild-type protein with minor
modification.29 Briefly, denatured 11F8 variants were isolated from
the insoluble bacteria pellet and purified with Ni2+ agarose (Qiagen,
Santa Clarita, CA). Fractions containing protein were refolded by
rapid dilution (1:200) into DNA binding buffer (50 mM NaHPO4,
pH 8, 150 mM NaCl, 0.1 mM TCEP (Tris (2-carboxyethyl) phos-
phine, hydrochloride)), containing oxidized glutathione (0.4 mM),
reduced glutathione (4 mM), and 1% v/v single-stranded DNA aga-
rose matrix with stirring for >24 h at 48C.32 The solution was
poured through a fritted glass column to isolate protein bound
resin. Resin was washed with five column volumes of DNA binding
buffer containing 400 mM NaCl. Folded protein was eluted from
the ssDNA column with DNA binding buffer containing NaCl (2M)
FIGURE 1 DNA ligands used in binding studies. Binding site
selection experiments were conducted with 11F8 and 55-nucleotide
long ssDNA constructs possessing a seven nucleotide-long random
insert.25 DNA of known sequence designed to prevent formation of
stable secondary structure flanked the random region. Mutations
produced during PCR amplification at multiple sites within the
constant region afforded a stable secondary structure that was
selected for by 11F8. 1 is the consensus sequence obtained from
these experiments.25 Additional nucleotides that initially flanked the
stem-loop were PCR primers used in the selection experiments and
were removed for these studies. Affinity and rate experiments were
completed with 21-mer hairpin sequences as shown. Truncation
does not increase affinity or alter binding properties.26,27 In T7,
positions 3, 8–14, and 16 of 1 are replaced with T.
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and urea (2M) and immediately exchanged into conjugation buffer
(50 mM NaHPO4, 150 mM NaCl, 0.1 mM TCEP, pH 8.0) with dial-
ysis. Protein was >98% pure by SDS-PAGE analysis, and was con-
centrated with Amicon Ultra YM10 membrane (Millipore, Bedford,
MA) to micromolar concentrations. Purified cysteine mutants were
stored at 808C or conjugated to fluorophore as described below.
Each 11F8 cysteine variant (15–100 lM) was conjugated to fluo-
rescein-5-maleimide (Molecular Probes, Eugene, OR). Fluorescein-
5-maleimide was dissolved (50 mg/mL) in DMSO and 503 molar
excess was added to a stirring solution of concentrated folded
protein in conjugation buffer. The reaction proceeded at room tem-
perature for 2 h with stirring and then 48C for an additional 18 h.
Free dye was removed with a P-10 column, 2.5 mL bed volume
(Amersham, Piscataway, NJ) that had been equilibrated in conjuga-
tion buffer. Protein was dialyzed against 4 L of conjugation buffer
for 24 h. The degree of labeling was calculated for each 11F8 variant
by comparing the protein absorbance at 280 nm (extinction coeffi-
cient of 11F8 is 51,970 cm1 M1)33 with absorbance at 495 nm
(extinction coefficient of fluorescein 83,000 cm1 M1),34 and
correcting for the UV absorbance contributed by fluorescein at
280 nm. The labeling efficiencies for 11F8 variants ranged from 60
to 90%. Site-specificity of labeling was confirmed with wild-type
11F8 control labeling reactions, which showed no dye conjugation.
Synthesis, Purification, and Labeling of 1 Variants
Tetramethylrhodamine labeled C121 variant was synthesized con-
taining a single copy of the modified base Amino-Modifier C6 dC
(Glen Research, Sterling, VA) using standard phosphor-amidite
chemistry. C121 was purified to >95% by HPLC as previously
described.17 Prior to conjugation, DNA was ethanol precipitated
to remove reactive buffer salts. Each modified oligonucleotide was
alkylated with 5-carboxytetramethylrhodamine succinimidyl ester
(5-TAMRA SE, Molecular Probes, Eugene, OR). Briefly, 100 lg of
a 25 mg/mL stock of each oligonucleotide in H2O was alkylated
with 200 lg of 5-TAMRA dissolved in 14 lL DMSO in 0.1M so-
dium tetraborate, pH 8.5, labeling buffer with a total reaction vol-
ume of 100 lL. The reaction proceeded at room temperature with
stirring for 8 h. Each reaction mixture was precipitated twice with
EtOH, and labeled oligonucleotides were purified by reverse-
phase HPLC using a Platinum EPS C8 column (Alltech, Deerfield,
IL) equilibrated at 95% 0.1M triethylammonium acetate, pH 6.6,
and acetonitrile. DNA was eluted with a linear gradient from 5 to
65% acetonitrile over 30 min. Subsequent analytical reverse-phase
analysis showed that each TAMRA-labeled oligonucleotide was
>95% pure. Each oligonucleotide was equilibrated with 4M NaCl
for 12 h to ensure that all backbone counterions were Na2+ and
sequences were desalted with a 2.5 mL bed volume PD-10 column
(Amersham, Piscataway, NJ).
Equilibrium Fluorescence Affinity Measurement
Fluorescence measurements were carried out on a Spectronic AB2
fluorometer equipped with a magnetic stirrer and a thermostated
cell block.35 Briefly, 11F8 was diluted into titration buffer (20 mM
Tris, 150 mM NaCl, pH 8.0) and equilibrated at 258C. The intrinsic
protein fluorescence (kex 280 nm; 4 nm bandpass, kem 336 nm;
16 nm bandpass) was measured as a function of added DNA. No
correction for the inner filter effect was necessary due to nonprohi-
bitive absorbance of DNA. Analysis of the binding isotherms has
been described elsewhere.35
Equilibrium Fluorescence Anisotropy Measurements
The fluorescence anisotropy of each of the six fluorescein labeled
11F8 mutants and tetramethylrhodamine labeled C12R1 was deter-
mined first as a single species, then in complex with unlabeled 1 and
11F8, respectively, and finally in complex with C12R1 and each F11F8
mutant, respectively. Excitation and emission bandpass filters were
utilized to observe the anisotropies of fluorescein (ex. 480 6 10 nm;
em. 530 6 10 nm; Andover Corporation, Salem, NH) and tetrame-
thylrhodamine (ex. 560 6 10 nm; em. 590 6 10 nm) in isolation.
Titration of F11F8 and C12R1 with >10-fold excess of labeled DNA
and protein, respectively, resulted in the same anisotropies as
observed with 1 : 1 molar equivalents so that experiments were com-
pleted with equimolar amounts of 11F8 and 1. The anisotropy of
each complex (20 nM 11F8 or mutant and 20 nM 1 or variant) was
measured, after equilibrating at room temperature for 5 min, as an
average of 25 scans using a Beacon 2000 Fluorescence Polarization
System (Invitrogen, Carlsbad, CA). Fluorescein and tetramethylrhod-
amine anisotropies for all F11F81, 11F8C12R1, and F11F8C12R1
complexes were 0.20 validating the assumption of free fluorophore
rotation upon complex formation as basis for using Förster theory in
our stopped-flow FRETenergy transfer analysis.36
Stopped-Flow FRET
Stopped-flow FRET experiments were conducted using a p-CDF
stopped-flow spectrophotometer from Applied Photophysics
(Surrey, UK). The sample-handling unit was fitted with 2 mL
syringes to give a mixing ratio of 1 : 1 v/v. In all cases, the fluores-
cein donor was excited with a Hg/Xe lamp at 436 nm (for optimal
lamp intensity) using a 1.5 nm slit width, and 1000 data points were
collected for each measurement over 5 s. The time-dependent change
in FRET (tetramethylrhodamine fluorescence) was monitored using
a 570 nm cutoff filter to eliminate any contribution from direct flu-
orescein excitation. Background correction was completed for each
trace to remove any contribution from direct tetramethylrhodamine
excitation. All measurements were made in 20 mM Tris-HCl, pH
8.0, 150 mM NaCl, 20% w/v sucrose at 58C, and at least eight inde-
pendent measurements were analyzed both individually and as an
average by single or double exponential curve fitting algorithms. In
experiments to determine the association rates for complex forma-
tion, [11F8] ¼ 200 nM (prior to mixing) while the DNA was main-
tained in at least 10-fold excess [2, 2.5, 3.0, and 3.5 lM] to approxi-
mate pseudo-first-order reaction conditions. The second-order rate
constant k2 was calculated form the slope of kapp versus [DNA].
RESULTS
Selection of Fluorescent Probe Locations
To enable the FRET studies, sites for fluorescent probe attach-
ment were determined for both 11F8 and 1 that did not per-
turb final complex formation. Antigen recognition primarily
occurs through residues located in the six CDRs of the heavy
and light chain variable regions.37 A cysteine was introduced
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via site directed mutagenesis either directly into or as close as
possible to each of the six CDRs. Residues were selected for
cysteine mutation based on a >50% relative solvent accessible
surface area excluding residues that maintain canonical CDR
structure or participate in CDRCDR interactions to avoid
introducing gross structural changes into the binding site.38
On the basis of these criteria, cysteine mutations within
HCDR1, HCDR2, and LCDR3 afforded reporters at T30CVH,
S53CVH, and
T94CVL respectively. However, cysteine mutation
to each loop residue in LCDR1, LCDR2, and HCDR3 ren-
dered unstable protein or a mutant that did not bind 1.
Mutations to neighboring framework regions accessed cyste-
ine mutants that did not perturb binding affinity. The closest
HCDR3 reporter, Q105CVH, is three amino acids away from
HCDR3, the closest LCDR1 reporter, S10CVL, is 13 amino
acids away from LCDR1, and the closest LCDR2 reporter,
S60CVL, is four amino acids away from LCDR2. The cytosine
that forms the loop closing of base pair 1 (C121) was selected
as the reporter of DNA conformation to afford six different
donoracceptor reporters for relative conformational changes
between 11F8 and 1 during association (Figure 2).
When 11F8 and related mAbs bind DNA, a quench in
tryptophan fluorescence is observed due to changes in the
microenvironment of W33VH in the binding pocket.
27 Bind-
ing affinity of the fluorescein and tetramethylrhodamine la-
beled variants was determined by monitoring the quench in
trypotphan fluorescence upon complex formation. The affin-
ity of the 11F81 complex was not significantly affected by
labeling in any of the six double-labeled complexes (Table I).
In all cases, the fluorescein fluorescence was monitored and
did not change throughout titration of ssDNA. Docking
experiments suggest somatic mutation from serine to argi-
nine at 31VH may result in more extensive conformational
changes during recognition.30 A second mutation from argi-
nine to serine was introduced at 31VH in each of the six 11F8
loop reporters to determine the dynamics of the R31S11F81
complex. Binding affinity of double mutants was not deter-
mined because it has been established that the R31SVH muta-
tion decreases affinity, and the objective of these experiments
was to monitor the structural effects of reversion mutation.29
However, previous studies suggest that little cooperativity
exists between residues of 11F8.29 Thus, we do not anticipate
that cooperativity between any of these double mutants con-
tribute to binding affinity.29,39
Stopped-Flow Fluorescence Resonance Energy
Transfer
The quench in tryptophan fluorescence upon 11F81 associ-
ation has also been utilized to determine the rate constants
for complex formation by stopped-flow.27 Recognition of 1
by 11F8 proceeds in two steps: formation of an encounter
complex, followed by a slow rate-limiting step that results in
the high-affinity complex observed at equilibrium as shown
in Scheme 1.27 Kinetic parameters for related mAbs revealed
that in the absence of a basic residue at 31VH, recognition of
1 results in a single decrease in tryptophan fluorescence. The
rates of the single step are slow and independent of [1] and
thus correspond to rate limited formation of the high affinity
complex (k2) in 11F81 recognition. These findings suggest
that the loss of electrostatic contacts from a basic side chain
coupled with the loss of a salt bridge to orient the ensuing
FIGURE 2 Schematic displaying the location of donor probes for
stopped-flow FRET. The light chain variable region is shown in light
gray and the variable heavy chain is shown in dark gray. Site-specific
fluorescein attachment sites are labeled as green spheres.















1 1.6 6 0.4 2.2 6 1.4 (1.5) 0.7 6 0.4 (0.5) 2.5 6 0.8 (1.6) 1.3 6 0.6 (0.9) 1.5 6 0.4 (0.9) 0.9 6 0.3 (0.6)
C121 4.2 6 0.7 (2.6) 4.4 6 0.5 (2.8) 1.8 6 0.1 (1.1) 4.1 6 1.4 (2.6) 4.2 6 1.0 (2.6) 4.3 6 0.5 (2.7) 3.7 6 0.6 (2.3)
Binding affinity was measured in 20 mM Tris, 150 mM NaCl, pH 8.0 at 25 8C. Relative Kd values are normalized against the Kd for the wild-type 11F81
complex and are listed in parentheses. Errors in Kd are standard deviations derived from a minimum of three independent assays.
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complex results in an altered association and likely confor-
mation of the encounter complex. We used FRET to deter-
mine if conformational changes at the interface were medi-
ated by 31VH. Because individual steps in the 11F8 reaction
pathway have discernable rates, we hypothesized that con-
certed structural changes accompanying complex formation
could be resolved to specific steps based upon rate constants.
Our approach was to combine FRET and pre-steady-state
kinetics to monitor the energy transfer of six different
donoracceptor pairs. Stopped-flow FRET cannot distin-
guish a priori between contributions to energy transfer
resulting from inter-fluorophore distance changes with
respect to more subtle fluorophore changes that are sensitive
to binding events, but not related to biopolymer dynamics.
Control experiments were completed to rule out a significant
contribution to energy transfer by process such as change in
fluorophore mobility or hydrophobicity of the solvent envi-
ronment. Briefly, fluorescein and tetramethylrhodamine ani-
sotropies for all F11F81, 11F8C12R1, and F11F8C12R1 com-
plexes were 0.20, validating the use of Förster theory for
energy transfer studies (Table II). Additionally, background
fluorescence of the donor only F11F81 and acceptor only
11F8C12R1 were subtracted from the FRET of each double-
labeled F11F8C12R1 complex, where F11F8 and C12R1
describe fluorescein labeled and tetramethylrhodamine la-
beled variants, respectively. Tetramethylrhodamine fluores-
cence resulting from energy transfer for each F11F8C12R1
complex was fit with either single or double exponential
curve fitting algorithms.
Similar to the quench in tryptophan fluorescence upon
11F81 association, the increase in tetramethylrhodamine
fluorescence during F11F8R1 recognition is biphasic
(Figure 3). Although FRET association rates do not directly
correspond with those obtained via tryptophan fluorescence,
similar trends exist (Table III).27 The initial fast increase
in tetramethylrhodamine fluorescence is followed by a
second slower increase in fluorescence. For five of the six
complexes, k1 was significantly faster than k2. One complex
HCDR3F11F8C12R1 resulted in only a single exponential tetra-
methylrhodamine response that was independent of [1]. In
all cases the rate of the initial phase (k1) varied linearly with
[1] typical of a bimolecular association process, and the rate
of the second phase (k2) was independent of [1]. As
suggested previously for 11F8, it is likely that k2 represents
the formation of the high affinity complex.27 Because FRET
during association can be broken down into the two
steps used to characterize 11F81 association, amplitudes of
each step describe the qualitative conformational changes
throughout complex formation.
Stopped-flow FRET measures relative distance changes
between two points rather than absolute distances, and
describes the concerted movement of both an 11F8 CDR and
1 with respect to each other. Since energy transfer is distance
dependent, fluorescein donor and tetramethylrhodamine
acceptor fluorophores must be within *80 Å for energy
transfer. Therefore, stopped-flow FRET cannot fully describe
the association process because a portion of k1 could occur
before the detection limit of the method is achieved for par-
ticular donor–acceptor pairs. Direct comparison of k1 is
therefore impossible to evaluate, since the extent to which k1
is observed is unknown. Alternatively, rate constants for the
slow phase, k2, were measured with good agreement between
all of the six donor–acceptor pairs (1.1 6 0.05 s1). FRET
amplitudes indicate conformational change in the second
step and lend further support that k2 describes conforma-
Table II Fluorescence Anisotropies of Fluorescein and Tetramethylrhodamine Probes Determined Individually for Each Fluorophore
and Complex
Anisotropy Conditions 11F8 HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3
1
Donor alone, Fluorescein
NA .10 6 .001 .11 6 .001 .08 6 .001 .10 6 .006 .10 6 .005 .07 6 .002
C12R1
Acceptor alone, Rhodamine
.16 6 .002 NA NA NA NA NA NA
F11F8C12R1
Double labeled, Fluorescein
NA .11 6 .004 .12 6 .001 .07 6 .004 .10 6 .002 .11 6 .003 .05 6 .005
F11F8C12R1
Double labeled, Rhodamine
NA .20 6 .001 .19 6 .001 .15 6 .001 .20 6 .002 .20 6 .002 .15 6 .001
Errors are the standard deviations for a minimum of three independent assays.
SCHEME 1
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tional adjustments during the progression from encounter
complex to high affinity complex as hypothesized. The rates
and amplitudes for k2 were compared to evaluate the relative
dynamics between 11F8 CDRs and 1 (Table III). It is interest-
ing to note that HCDR1F11F8C12R1, LCDR1F11F8C12R1, and
LCDR2F11F8C12R1 undergo greater conformational change
during complex formation than the other three CDRs and 1
(Figure 4).
When a single somatic mutation is reverted to germline
(R31SVH), 11F8 loses sequence-specificity, and the thermody-
namic and kinetic parameters for ssDNA recognition resem-
ble the clonally related, nonsequence-specific, nonpathogenic
mAbs 9F11 and 15B10.28 Both 9F11 and 15B10 have a serine
side chain at 31VH. To investigate the dynamics of the CDRs
during complex formation in the absence of arginine, six cor-
responding R31SF11F8C12R1 complexes bearing mutation to
serine and conjugated to fluorescein were monitored by
stopped-flow FRET (Table IV). A single exponential fluores-
cence response was expected based upon previous observa-
tions that removal of a basic side chain at 31VH resulted in a
single exponential quench in tryptophan fluorescence.26
When observed, the change in tetramethylrhodamine fluo-
rescence for the double mutants fit a single exponential
with a rate independent of [1]. Rates for k2 were similar to
those observed with arginine instead of serine at 31VH. These
data provide further support that a rate-limiting con-
formational change is observed both in the presence and
absence of arginine.
Because FRET efficiency directly correlates to distance,
changes in FRETefficiency (indicated by an increase or decre-
FIGURE 3 Stopped-flow fluorescence data for the interaction between 11F8 and 1. (A) Associa-
tion trace for the interaction between 11F8 (200 nM) and 1 (2 lM). The excitation wavelength was
set at 280 nm to monitor the decrease in tryptophan fluorescence. The initial fast change in fluores-
cence has a rate of 23.4 6 2.1 s1, whereas the rate of the second slow signal change is 4.9 6 0.4
s1. (B) Linear dependence of the initial rate (kapp) on [1]. The second order rate constant (k1)
describing the fast step (^) was calculated to be 9.4 6 0.8 s1 in 20% sucrose from the slope of the
plot. The second slower rate (n) was shown to be independent of [1] under pseudo-first-order con-
ditions. (C) Representative FRET association trace for the interaction between LCDR1F11F8 (200
nM) and C12R1 (2 lM). The excitation wavelength was set at 436 nm and rhodamine fluorescence
resulting from FRETwas measured above 570 nm. The initial fast change in fluorescence has a rate
of 9.1 6 0.6 s1, whereas the rate of the second slow signal change is 1.1 6 0.1 s1. (D) Linear de-
pendence of the rates (kapp) on. [1] The second order rate constant (k1) describing the fast step
(^) was calculated to be 3.9 6 0.3 s1 in 20% sucrose from the slope of the plot. The second
slower observed rate (n) was independent of [1] over the concentration range tested.
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ase in tetramethylrhodamine fluorescence as a result of energy
transfer) are related to the magnitude of conformational
change that occurs upon binding. While k2 for the serine
double mutants is similar, amplitudes are significantly
smaller and often in the opposite direction (decreases in tet-
ramethylrhodamine fluorescence are observed in R31S11F81
instead of increases as observed in 11F81) (Table IV). These
data suggest that in the absence of arginine at 31VH, donor
and acceptor fluorophores move slightly further apart as the
encounter complex reaches equilibrium. In two cases
(R31SHCDR1F11F8C12R1 and R31SLCDR2F11F8C12R1) there was
no change in tetramethylrhodamine fluorescence observed.
This donor and acceptor exhibit energy transfer at equilib-
rium (transfer efficiency of 0.67 6 0.1 and 0.48 6 0.2,
respectively) and so the absence of a change in transfer effi-
ciency cannot be attributed to a lack of FRET, but rather lack
of a detectable conformational change. Collectively, these
data suggest that without arginine at 31VH, there is less struc-
tural rearrangement at the binding site.
DISCUSSION
There are only a few high-resolution structures of anti-
nucleic acid autoantibodies and their respective mAbanti-
gen complexes: DNA-1dT3/5,7,31 BV04-01d(pT),5 and Jel
103rI.40 These three anti-ssDNA/RNA mAbs help describe
the components of nucleic acid recognition, and provide
insight towards antibody flexibility during binding. In partic-
ular, large structural differences between DNA-1 in complex
with either oligo thymine or HEPES salt suggests that confor-
mational flexibility accounts for specificity while a somatic








HCDR1F11F8C12R1 8.6 6 1.0 1.1 6 0.1 0.13 6 .02 0.29 6 .01
HCDR2F11F8C12R1 8.4 6 0.8 1.1 6 0.1 0.07 6 .04 0.10 6 .01
HCDR3F11F8C12R1 NO 1.0 6 0.1 NO 0.06 6 .01
LCDR1F11F8C12R1 3.9 6 0.3 1.1 6 0.1 0.12 6 .01 0.26 6 .01
LCDR2F11F8C12R1 9.8 6 1.0 1.1 6 0.1 0.14 6 .03 0.26 6 .01
LCDR3F11F8C12R1 1.6 6 0.2 1.0 6 0.3 0.02 6 .01 0.03 6 .01
Rate constants were measured in 20 mM Tris, 100 mM NaCl, pH 8.0, 20% w/v sucrose at 5 8C. HCDR3F11F8C12R1
association occurs in one step. The observed rate is independent of [1] and is related to the formation of the high affinity
complex (k2) in 11F81 association, which is also independent of [1]. The single association rate for HCDR3R11F8C12R1
is therefore reported as k2 for comparison. NO stands for not observed. Errors are standard deviations derived from a
minimum of eight traces.
FIGURE 4 Change in FRET amplitude during k2 for the six
F11F8C12R1 complexes in the presence (black) and absence (gray)
of binding site arginine at 31VH. The CDR location of fluorescein is
described by HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and
LCDR3 while the rhodamine probe is located on C12 (C121).
Table IV Rate Constant and FRETAmplitudes Measured
During R31SF11F8R1 Association
Complex k2 (s
1) Amp k2 (Fluorescence Units)
HCDR1F11F8C12R1 2.5 6 1.0 0.03 6 .01
HCDR2F11F8C12R1 – –
HCDR3F11F8C12R1 – –
LCDR1F11F8C12R1 0.2 6 0.1 0.04 6 .01
LCDR2F11F8C12R1 1.1 6 0.1 0.05 6 .01
LCDR3F11F8C12R1 1.3 6 0.3 0.05 6 .01
Rate constants were measured in 20 mM Tris, 100 mM NaCl, pH 8.0, 20%
w/v sucrose at 5 8C. (–) indicate complexes where no change in energy trans-
fer is observed. When a change in energy transfer is observed, it always fits a
single exponential. Since the observed rate is independent of [1] it is related
to the formation of the high affinity complex (k2) in 11F81 association,
which is also independent of [1]. The single association rate is therefore
reported as k2 for comparison. Decreases (shown in italic) in rhodamine
fluorescence are observed. Errors are standard deviations derived from a
minimum of eight traces.
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mutation helps to lock certain ligands into an optimal bind-
ing site.7 Consistent with our observations of increased con-
formational change following somatic mutation, Schuer-
mann et al. suggest that structural plasticity could provide a
mechanism by which anti-DNA antibodies can access bind-
ing sites for diverse host ligands, and thereby contribute to
pathogenicity.7
The body of work describing the binding properties of
9F11, and 15B10 suggests that similar to BV04-01, DNA-1,
and Jel 103, these mAbs utilize Y32VL, a hydrogen bonding
residue at 91VL, and an aromatic side-chain at the tip of
HCDR3 to bind ssDNA.28,30 Crystal structures of BV04-01,
DNA-1, and Jel 103 complexes reveal a nucleotide sand-
wiched between two aromatic residues in the binding pocket.
Interestingly, both BV04-01 and DNA-1 use two binding site
residues to flank a single thymine nucleotide (although mul-
tiple thymine residues are available), and Jel 103 stacks with
a single nucleotide as well (although the Jel 103 crystal was
soaked with rI nucleotides). Similar to 9F11 and 15B10, both
DNA-1, and Jel103 have a serine at 31VH whereas BV04-01
has a threonine. A model of the R31S11F81 complex (struc-
turally similar to 9F11 and 15B10) suggests that Y32VL,
H91VL, and
Y100VH at the tip of HCDR3 interact with 1.
30 It is
likely that 9F11 and 15B10 recognition of ssDNA occurs
through the common structural hot spot observed in the
BV04-01, DNA-1, and Jel 103 complexes.
While other ssDNA binding proteins differ from anti-
DNA autoantibodies in the secondary structural motifs that
interact with DNA, they often utilize both surface comple-
mentarity and conformational change. For example, Oxytri-
cha nova telomere end binding protein (OnTEBP) binds
ssDNA with high affinity (nM-pM) and sequence-specificity
through extensive surface complementarity and conforma-
tional change.41,42 Structural comparisons of both cognate
and noncognate OnTEBPssDNA complexes revealed exten-
sive binding site reorganization to accommodate cognate vs.
noncognate nucleic acid sequences.43 Additionally, the TraI
protein is similar to the variable heavy chain of 11F8 and clo-
nally related mAbs 9F11 and 15B10 in that despite high
sequence homology in related TraI domains (for recognition
of F or R100 plasmid DNA), sequence variability at only two
positions entirely mediates unique specificities. Two different
Tral domains containing either R193/Q201 (F) or Q193/
R201 (R100) discriminate between binding sites that differ
by two of eleven nucleotides.44 Mutating these two side
chains located on opposite sides of the binding site (R193Q/
Q201R in F or Q193R/R201Q in R100) confers specificity for
the noncognate site over the cognate site in both cases.45
Somatically mutated R31VH is located at the periphery of
the 11F8 binding pocket and several lines of evidence suggest
that it forms a salt bridge with the ssDNA backbone.26,28–30
Together with conserved R98VH,
R31VH likely facilitates dual
salt bridge contacts to orient the ensuing sequence-specific
11F81 complex. The 11F81 and R31S11F81 models suggest
that conformation and contact changes facilitated by the
S31RVH somatic mutation results in recognition in part simi-
lar but also unique from other anti-ssDNA. We hypothesize
that the R31VH salt bridge with 1 affords sequence and regis-
ter discrimination in the encounter complex. The 11F81
model proposes interactions between R31VH and 1 cause loss
of interaction with 91VL and gain of direct contacts with side
chains in VH, not previously associated with ssDNA recogni-
tion (W33VH,
R96VH, and
L97VH), collectively shifting the
binding site towards the heavy chain.30
A change in specific heat upon complex formation can be
attributed to increased burial of hydrophobic surface area,
and in some cases conformational change.46 Because the
model of the 11F81 complex and the model of the
R31S11F81 complex suggest similar buried surface areas, dif-
ferences in specific heat capacity upon ssDNA binding could
be indicative of conformational change. Comparison of
changes in specific heat capacity upon recognition of 1 versus
a thymine-rich ligand (T7) by 11F8, 9F11, and 15B10 is con-
sistent with conformational change during sequence-specific
recognition of 1.46 When 11F8, 9F11, and 15B10 bind to T7
there is no DCP, even though a significant amount of hydro-
phobic surface area is occluded when aromatic side chains
stack with thymine at the interface. 9F11 and 15B10 recogni-
tion of 1 occurs with no DCP similar to recognition of T7.
However, the DCP for 11F8 binding to 1 is accompanied by
DCP (1.3 kcal mol1 K1), which supports our FRET
data suggesting greater conformational change during
sequence-specific recognition of 1.35
Collectively, structural modeling and FRET data propose
that altered surface complementarity is achieved through
R31VH dependent conformational rearrangement during
sequence-specific recognition of 1 by 11F8. The model of the
11F81 complex together with mutagenesis data indicate a
second thymine stacks between Y100VH and
W33VH, and that
direct contacts exist between the guanidinium side chain and
base edge hydrogen bond acceptors, both of which do not
exist in the model of R31S11F81. These data imply that
R31VH affords 11F8 sequence-specificity in part by mediating
conformational change, and together with sequence-specific
contacts, may mediate the transition from nonpathogenic to
pathogenic phenotype for a lupus autoantibody.
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